NCT00210600View on ClinicalTrials.gov

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

August 31, 2006

Conditions
Anemia
Interventions
DRUG

PROCRIT (Epoetin alfa)

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210600 - Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy | Biotech Hunter | Biotech Hunter